ArticlePharmaceutics2020

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC.

Nam Ah Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.